Development of immnotherapy for gynecological cancer and microenvironment

2014 Fiscal Year Final Research Report

• Project/Area Number: 24592512
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Obstetrics and gynecology
• Research Institution: Nagoya University
• Principal Investigator: SHIBATA Kiyosumi 名古屋大学, 医学(系)研究科(研究院), 准教授 (90335026)
• Co-Investigator(Kenkyū-buntansha): KAJIYAMA Hiroaki 名古屋大学, 大学院医学系研究科, 准教授 (00345886)
• Project Period (FY): 2012-04-01 – 2015-03-31
• Keywords: 癌免疫療法 / 癌微小環境 / 腹膜播種 / 免疫抑制 / 臨床試験

Outline of Final Research Achievements

We performed a phase II clinical trial of HLA-A24 and A2 restrictive Glypican-3 (GPC3) peptide vaccine for 92 ovarian clear cell carcinoma patients as one of the immunotherapy for refractory ovarian carcinoma. We confirmed three partial responses in a advanced patient. However our resuths showed that the patients with peritoneal dissemination had slightly effectiveness of peptide vaccine. We investigated the interaction between ovarian clear cell carcinoma cells and peritoneal cells. We showed that the expressions of VEGF, IL-6 and IL-8 elevated and the functions of CD8 possitive T cells (CTL) were decreased. Our results showed that peritoneal dissemination of ovarian carcinoma was immunosuppresive environment.

Free Research Field

婦人科腫瘍学